Discovery and Hit-to-Lead Optimization of Benzothiazole Scaffold-Based DNA Gyrase Inhibitors with Potent Activity against <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i>-Reference-Cited by-同舟云学术

Discovery and Hit-to-Lead Optimization of Benzothiazole Scaffold-Based DNA Gyrase Inhibitors with Potent Activity against Acinetobacter baumannii and Pseudomonas aeruginosa

Published:2023-01-12 Issue:2 Volume:66 Page:1380-1425
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Cotman Andrej Emanuel¹^ORCID,Durcik Martina¹^ORCID,Benedetto Tiz Davide¹,Fulgheri Federica¹^ORCID,Secci Daniela¹,Sterle Maša¹^ORCID,Možina Štefan¹^ORCID,Skok Žiga¹,Zidar Nace¹^ORCID,Zega Anamarija¹^ORCID,Ilaš Janez¹^ORCID,Peterlin Mašič Lucija¹,Tomašič Tihomir¹^ORCID,Hughes Diarmaid²,Huseby Douglas L.²^ORCID,Cao Sha²,Garoff Linnéa²,Berruga Fernández Talía²^ORCID,Giachou Paraskevi²,Crone Lisa²,Simoff Ivailo³^ORCID,Svensson Richard³,Birnir Bryndis⁴,Korol Sergiy V.⁴^ORCID,Jin Zhe⁴,Vicente Francisca⁵,Ramos Maria C.⁵^ORCID,de la Cruz Mercedes⁵,Glinghammar Björn⁶,Lenhammar Lena⁷,Henderson Sara R.⁸^ORCID,Mundy Julia E. A.⁸,Maxwell Anthony⁸^ORCID,Stevenson Clare E. M.⁸,Lawson David M.⁸,Janssen Guido V.⁹,Sterk Geert Jan⁹,Kikelj Danijel¹

Affiliation:

1. Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia

2. Department of Medical Biochemistry and Microbiology, Uppsala University, Husargatan 3, 75123 Uppsala, Sweden

3. Drug Optimization and Pharmaceutical Profiling Platform (UDOPP), Department of Pharmacy, Uppsala University, Husargatan 3, 75123 Uppsala, Sweden

4. Department of Medical Cell Biology, Uppsala University, Husargatan 3, 75123 Uppsala, Sweden

5. Fundación MEDINA, Avenida del Conocimiento 34, Parque Tecnológico Ciencias de la Salud, 18016 Granada, Spain

6. Department Chemical Process and Pharmaceutical Development, Unit Chemical and Pharmaceutical Safety, RISE Research Institutes of Sweden, 15136 Södertälje, Sweden

7. Department of Medical Sciences, Uppsala University Hospital, 75185 Uppsala, Sweden

8. Department of Biochemistry and Metabolism, John Innes Centre, Norwich Research Park, Norwich NR4 7UH, U.K

9. Medicinal Chemistry Division, Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081 HZ Amsterdam, The Netherlands

Funder

Javna Agencija za Raziskovalno Dejavnost RS

Innovative Medicines Initiative

Wellcome Trust

Biotechnology and Biological Sciences Research Council

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c01597

Reference59 articles.

1. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis https://www.who.int/publications/i/item/WHO-EMP-IAU-2017.12 (accessed May 3, 2022).

2. The global preclinical antibacterial pipeline

3. Analysis of the clinical antibacterial and antituberculosis pipeline

4. Antibiotics in the clinical pipeline in October 2019

5. Exploiting bacterial DNA gyrase as a drug target: current state and perspectives

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Benzothiazole DNA gyrase inhibitors and their conjugates with siderophore mimics: design, synthesis and evaluation;RSC Advances;2024

2. Discovery and druggability evaluation of pyrrolamide-type GyrB/ParE inhibitor against drug-resistant bacterial infection;Acta Pharmaceutica Sinica B;2023-12

3. Computational Analysis on Molecular Stability and Binding Affinity of 3-(Aminothiazolyl)Quinolone Derivative as Multitargeting Antibacterial Agents through Ab Initio Methods and Molecular Docking;Polycyclic Aromatic Compounds;2023-10-25

4. A Three‐Step Chemoenzymatic Cascade Synthesis of Miconazole Analogues Based on the Asymmetric Synthesis of β‐Heteroaryl Amino Alcohols via Ketoreductases;Advanced Synthesis & Catalysis;2023-09-21

5. Exploring the 5-Substituted 2-Aminobenzothiazole-Based DNA Gyrase B Inhibitors Active against ESKAPE Pathogens;ACS Omega;2023-06-28